What is OnLume?
Founded in 2015, OnLume specializes in the design and manufacture of advanced surgical devices. The company's core value proposition centers on its fluorescence-guided surgery (FGS) imaging system, a sophisticated platform designed to provide real-time visualization of blood flow and tissue perfusion. By enabling surgeons to observe physiological markers before, during, and after complex procedures, OnLume addresses critical needs in microsurgery and organ transplantation. The company operates at the intersection of medical imaging and surgical robotics, positioning itself as a vital player in the high-growth field of intraoperative diagnostics.
How much funding has OnLume raised?
OnLume has raised a total of $15.1M across 3 funding rounds:
Other Financing Round
$749K
Unspecified
$7.3M
Series A
$7M
Other Financing Round (2019): $749K, investors not publicly disclosed
Unspecified (2021): $7.3M, investors not publicly disclosed
Series A (2021): $7M supported by Wisconsin Investment Partners, WARF Ventures, and Cambridge Investment Group
Key Investors in OnLume
Wisconsin Investment Partners
Wisconsin Investment Partners is a prominent angel investment group and business incubator that provides essential capital and mentorship to early-stage ventures within the regional entrepreneurial ecosystem.
Cambridge Investment Group
Cambridge Investment Group is a specialized investment firm focused on identifying and cultivating strategic opportunities for individual investors across various asset classes.
WARF Ventures
WARF Ventures is an investment arm dedicated to supporting innovation and commercializing research-based technologies, often acting as a catalyst for high-potential medical and scientific startups.
What's next for OnLume?
With the recent capital deployment, OnLume is expected to prioritize the commercial scaling of its FGS platform. The strategic roadmap likely includes expanding the regulatory footprint of its imaging technology and deepening its penetration into major hospital networks. As the company transitions from a development-focused entity to a commercial-stage enterprise, the focus will shift toward clinical validation studies and the optimization of its supply chain to meet the rising demand for high-fidelity surgical visualization tools. This growth phase is critical for establishing OnLume as a standard-bearer in the evolving landscape of precision medicine.
See full OnLume company page
